Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Authors
Tannock, IFizazi, K
Ivanov, S
Karlsson, C
Fléchon, A
Skoneczna, I
Orlandi, F
Gravis, G
Matveev, V
Bavbek, S
Gil, T
Viana, L
Arén, O
Karyakin, O
Elliott, Tony
Birtle, A
Magherini, E
Hatteville, L
Petrylak, D
Tombal, B
Rosenthal, M
Affiliation
Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: ian.tannock@uhn.ca.Issue Date
2013-07
Metadata
Show full item recordAbstract
Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor, thereby inhibiting angiogenesis. We assessed whether the addition of aflibercept to docetaxel and prednisone would improve overall survival in men with metastatic castrate-resistant prostate cancer compared with the addition of placebo to docetaxel and prednisone.Citation
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. 2013, 14 (8):760-8 Lancet OncolJournal
Lancet OncologyDOI
10.1016/S1470-2045(13)70184-0PubMed ID
23742877Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(13)70184-0